CCR5抑制剂leronlimab治疗结肠癌具有显著优势

2019-08-04 Allan MedSci原创

CytoDyn公司开发的leronlimab(PRO 140)是一种具有治疗多种适应症潜力的CCR5拮抗剂,CytoDyn公司近日宣布leronlimab(PRO140)在人源化小鼠模型中治疗人结肠癌的研究取得了成功。

CytoDyn公司开发的leronlimabPRO 140)是一种具有治疗多种适应症潜力的CCR5拮抗剂,CytoDyn公司近日宣布leronlimabPRO140)在人源化小鼠模型中治疗人结肠癌的研究取得了成功。

现有数据表明,结肠癌肿瘤的快速生长与CCR5高表达相关,并且leronlimab可以抑制肿瘤细胞中CCR5的表达以抑制结肠癌生长。CytoDyn总裁兼首席执行官Nader Pourhassan博士说:我们宣布的结果为肿瘤学提供了潜在的重要机遇。考虑到医疗需求高度未得到满足,我们对leronlimab所取得的结果感到鼓舞


原始出处:

http://www.firstwordpharma.com/node/1656539#axzz5vaProhET

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852072, encodeId=71da18520e27b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 11 19:15:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912182, encodeId=b07a191218217, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 21 18:15:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581162, encodeId=ab91158116259, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Tue Aug 06 00:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
    2019-11-11 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852072, encodeId=71da18520e27b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 11 19:15:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912182, encodeId=b07a191218217, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 21 18:15:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581162, encodeId=ab91158116259, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Tue Aug 06 00:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
    2019-09-21 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1852072, encodeId=71da18520e27b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 11 19:15:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912182, encodeId=b07a191218217, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 21 18:15:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581162, encodeId=ab91158116259, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Tue Aug 06 00:15:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]

相关资讯

单抗界的板蓝根?继HIV、乳腺癌后 leronlimab向NASH发起挑战!

CytoDyn是一家专注于开发新型人源化CCR5单克隆抗体leronlimab(PRO140)用于多种治疗适应症的生物技术公司。近日,该公司宣布与克利夫兰诊所的Daniel Lindne博士达成合作协议,在人源化小鼠模型中检测leronlimab预防非酒精性脂肪性肝炎(NASH)的能力。之前,辉瑞的一款HIV药物maraviroc在非酒精性脂肪性肝病(NAFLD)小鼠模型中已显示出可改善肝脏脂肪变

艾滋病预防新进展:CytoDyn和FDA将达共识以确定Leronlimab的关键单药治疗试验方案

CytoDyn一家开发Leronlimab的晚期生物技术公司,这是一种具有多种适应症治疗潜力的CCR5拮抗剂。CytoDyn近日宣布,美国FDA已要求举行面对面会议,讨论并可能最终确定CytoDyn最近提交的Leronlimab关键单药治疗试验方案。